[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
March 2018

Characterizing Kaiser Permanente Southern California’s Experience With the California End of Life Option Act in the First Year of Implementation

Author Affiliations
  • 1Kaiser Permanente Southern California, Pasadena, California
  • 2Southern California Permanente Medical Group, Kaiser Permanente School of Medicine, Pasadena, California
JAMA Intern Med. 2018;178(3):417-421. doi:10.1001/jamainternmed.2017.7728

The California End of Life Option Act (EOLOA),1 which took effect on June 9, 2016, allows qualified adults diagnosed with a terminal disease to request aid-in-dying drugs from their physician. The California Department of Public Health recently published data on 191 individuals who received aid-in-dying prescriptions during the act’s first 6 months.2 In response to recommendations for more comprehensive documentation of EOLOA implementation to improve end-of-life care,3 this study describes the experience of a large integrated health system and provides in-depth descriptions of individuals who initiated the EOLOA process.